ERBB2 and breast cancer: In the second one, E75 added to trastuzumab and GM-CSF was compared to trastuzumab plus GM-CSF alone in a randomized phase IIb trial which included HER2 low to intermediate-expressing (1+/2+) BC after completion of standard therapy.